Drug reference

copanlisib

PI3Kα and PI3Kδ isoform inhibitor · Antineoplastic agent

PI3Kα and PI3Kδ isoform inhibitorAntineoplastic agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
ApalutamideSevereDatabaseDDInter
AtazanavirSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter

Mechanism

Copanlisib is an inhibitor of PI3Kα and PI3Kδ isoforms that are expressed in malignant B cells. The efficacy of copanlisib has been linked to inhibition of nuclear factor-κB (NF-κB) signaling and reduced release of interleukin (IL)-6 and IL-10.

Indications

relapsed FL who have received at least two prior systemic therapies

Pharmacokinetics

Half-life

39.1 h (elimination)

Metabolism

CYP3A (substrate)

Side effects

Common

hyperglycemiahypertensiondecreased general strength and energy

Serious

pneumonitis
diarrhea

Pregnancy & lactation

Pregnancy

Drug interactions

Adalimumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Apalutamide

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Atazanavir

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Baricitinib

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Boceprevir

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Carbamazepine

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Ceritinib

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Certolizumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Cladribine

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Clarithromycin

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Clozapine

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Cobicistat

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Heart failure in diabetes

RSSDI · Cardiology · 2023

Systemic lupus erythematosus

EULAR · Rheumatology · 2023

Hypertension in adults

ICMR · Cardiology · 2019

Hypertrophic cardiomyopathy

ESC · Cardiology · 2026

Sjögren's syndrome

EULAR · Rheumatology · 2025

Ask House about copanlisib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10